This is from 2015 -
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412468/
"While a variety of different treatment regimens have been studied in an effort to improve outcomes of patients with RR-AML, there appears to be no single superior approach. We therefore believe that the only current standard of care for a patient with relapsed AML is to offer enrollment in a clinical trial"
Ann: First Patient Dosed in Phase 1b/2 AML Trial, page-47
-
- There are more pages in this discussion • 199 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
-0.080(4.12%) |
Mkt cap ! $315.1M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $367.9K | 195.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3965 | $1.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 1917 | 1 |
View Market Depth
| Last trade - 12.33pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |